Literature DB >> 6177960

Antihypertensive drugs and blood lipids: the Oslo study.

P Leren, I Eide, O P Foss, A Helgeland, I Hjermann, I Holme, S E Kjeldsen, P G Lund-Larsen.   

Abstract

The effects on blood lipids and uric acid of six different antihypertensive drugs used alone, and of five different combinations of two antihypertensive drugs, are reported here. Prazosin significantly lowered serum low density lipoprotein and very low density lipoprotein (LDL + VLDL) cholesterol and total triglycerides while maintaining high density lipoprotein (HDL) levels. Atenolol lowered LDL + VLDL cholesterol slightly. Both pindolol and hydrochlorothiazide (HCTZ) were neutral, while oxprenolol increased total triglycerides. Propranolol lowered HDL cholesterol and increased total triglycerides and uric acid. The combination of prazosin plus pindolol has a direct favorable lipid profile, while the combination of propranolol plus HCTZ lowered HDL cholesterol and increased total triglycerides. The combination of propranolol plus prazosin lowered HDL cholesterol, but to a lesser degree than propranolol alone, which suggests that prazosin was not able to completely counteract the negative effects of propranolol on HDL. Methyldopa plus HCTZ, and HCTZ plus amiloride were neutral with regard to effects on blood lipids. It is suggested that the metabolic effects of antihypertensive drugs could be of special importance in the long-term treatment of mild hypertension.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6177960

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  10 in total

Review 1.  Atenolol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.

Authors:  A N Wadworth; D Murdoch; R N Brogden
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

Review 2.  The management of hypertension.

Authors:  B N Prichard; C W Owens
Journal:  Br J Clin Pharmacol       Date:  1986       Impact factor: 4.335

3.  Hypertension. Current therapeutic practice reviewed.

Authors:  B N Prichard
Journal:  Drugs       Date:  1986       Impact factor: 9.546

Review 4.  Serum lipoproteins during treatment with antihypertensive drugs.

Authors:  P Weidmann; C Ferrier; H Saxenhofer; D E Uehlinger; B N Trost
Journal:  Drugs       Date:  1988       Impact factor: 9.546

5.  Association between sympathetic activity and the atherogenic serum cholesterol fraction.

Authors:  P Weidmann; D C Schohn; W Riesen; H A Jahn; P Ferrari; S G Shaw; C Beretta-Piccoli
Journal:  Klin Wochenschr       Date:  1990-03-05

Review 6.  The effects of antihypertensive drugs on serum lipids and lipoproteins, I. Diuretics.

Authors:  R P Ames
Journal:  Drugs       Date:  1986-09       Impact factor: 9.546

Review 7.  Adverse metabolic effects of antihypertensive drugs. Implications for treatment.

Authors:  H G Preuss; J F Burris
Journal:  Drug Saf       Date:  1996-06       Impact factor: 5.606

8.  Beta-blocker induced changes in the cholesterol: high-density lipoprotein cholesterol ratio and risk of coronary heart disease.

Authors:  B G Woodcock; N Rietbrock
Journal:  Klin Wochenschr       Date:  1984-09-17

9.  Oslo Hypertension Study.

Authors:  P Leren; A Helgeland
Journal:  Drugs       Date:  1986       Impact factor: 9.546

10.  δ-Tocotrienol and quercetin reduce serum levels of nitric oxide and lipid parameters in female chickens.

Authors:  Asaf A Qureshi; Julia C Reis; Nilofer Qureshi; Christopher J Papasian; David C Morrison; Daniel M Schaefer
Journal:  Lipids Health Dis       Date:  2011-02-28       Impact factor: 3.876

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.